Open access · CC-BY
via OpenAlex
From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention
Zhuowei Yu, Qingwei Ruan, Grazia D’Onofrio, Antonio Greco
InTech eBooks · 2017 · ▲ 13 citations
Deregulated nutrient-sensing
Altered intercellular communication
Caloric restriction
Rapamycin / mTOR inhibition
Metformin
Exercise
Partial reprogramming (OSK)
Human
Abstract
Skeletal muscle is not only an endocrine organ but also one of core components of muscloskeletal system. Sarcopenia refers to a decline in the skeletal muscle mass and function. The former involves the size and number of changes in two types of myofibers, lower satellite cell density, and regeneration ability. The latter shows a loss of muscle strength. Frailty is a geriatric syndrome with multisystem impairment associated with increased vulnerability to stressors. Sarcopenia increases the risk of frailty and may be one of the major causes of physical frailty phenotype. Sarcopenia is also potentially associated with cognitive frailty phenotype. Aging might be the common underlying pathophysiology of sarcopenia and frailty. Therefore, there are some potential target molecules in aging-related signaling pathways that might be associated with sarcopenia and frailty. Nevertheless, sarcopenia can mediate metabolism and promote accelerate systemic aging, frailty, and age-related diseases by myokines in an endocrine manner. Lifestyle interventions (resistance exercise and dietary restriction) of gerontoscience are effective in the prevention of sarcopenia. Some pharmacological agents are registered in different phases of clinical trials for sarcopenia intervention. Phytochemicals, mTOR(definition) inhibitors, metformin and acarbose, NAD precursors, and sirtuin activators demonstrated that multiple target antiaging effects might also have preventive and therapeutic perspectives on sarcopenia and frailty.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.5772/intechopen.69639
- Canonical
- link ↗
- Fetched
- 2026-06-29 MST
Cite this
APA
Yu, Z., Ruan, Q., D’Onofrio, G., & Greco, A. (2017). From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention. <em>InTech eBooks</em>. https://doi.org/10.5772/intechopen.69639
Vancouver
Yu Z, Ruan Q, D’Onofrio G, Greco A. From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention. InTech eBooks. 2017. doi:10.5772/intechopen.69639.
BibTeX
@article{zhuowei2017FromSa,
title = {From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention},
author = {Zhuowei Yu and Qingwei Ruan and Grazia D’Onofrio and Antonio Greco},
journal = {InTech eBooks},
year = {2017},
doi = {10.5772/intechopen.69639},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Endocrinology 2019
Open access · CC-BY
Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly
Zeitschrift für Gerontologie und Geriatrie 1999
Citation only
Sarcopenia, hypermetabolism, and aging
Elsevier eBooks 2016
Citation only
The Aging Muscle and Sarcopenia
Elsevier eBooks 2019
Citation only
Aging Muscle and Sarcopenia
Journal of Clinical Densitometry 2015
Preprint · OA
The Epidemiology of Sarcopenia
Clinics in Geriatric Medicine 2011
Citation only